{"analyses":[{"ciLowerLimit":"2.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Stratified by RET mutation type (M918T vs. Others) and intended treatment if randomized to Arm B (Vandetanib vs. Cabozantinib)","paramType":"Odds Ratio (OR)","paramValue":"3.7","statisticalMethod":"Clopper-Pearson method"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.4","upperLimit":"75.8","value":"69.4"},{"groupId":"OG001","lowerLimit":"29.1","upperLimit":"49.2","value":"38.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"193"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"ORR is defined as the number of participants who achieved the best overall response (BOR) of CR or PR divided by the total number of participants randomized to each treatment arm. ORR per RECIST 1.1 as assessed by BICR.","dispersionType":"95% Confidence Interval","groups":[{"description":"160 milligrams Selpercatinib administered orally (PO) twice daily (BID).\n\nAdolescent Dose: 92 mg/m2 BID (not to exceed 160 mg BID).","id":"OG000","title":"Selpercatinib (TRT A)"},{"description":"140 mg Cabozantinib administered orally daily (QD) or 300 mg Vandetanib administered orally QD per physician choice.\n\nCabozantinib Adolescent Dose: 40 mg/m2.\n\nVandetanib Adolescent Dose:\n\n* 0.7 - \\<0.9 - 100 mg every other day (QOD)\n* 0.9 - \\<1.2 - 100 mg QD\n* 1.2 - \\<1.6 - 7-day schedule 100 mg - 200 mg - 100 mg - 200 mg - 100 mg - 200 mg - 100 mg\n* ≥1.6 - 200 QD","id":"OG001","title":"Cabozantinib or Vandetanib (TRT B)"}],"paramType":"NUMBER","populationDescription":"All randomized participants, even if a participant did not take the assigned treatment, did not receive the correct treatment, or otherwise did not follow the protocol.","reportingStatus":"POSTED","timeFrame":"Baseline through Disease Progression or Death Up to 39 Months","title":"Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) by BICR","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}